Human chorionic gonadotropin: Different glycoforms and biological activity depending on its source of production.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms and physiology without original clinical data or systematic methodology.
PubMed 27177499 · doi:10.1016/j.ando.2016.04.012
What was done
This narrative review summarizes existing literature on the genetic structure, glycosylation profiles, cellular sources (syncytiotrophoblast versus invasive extravillous trophoblast), receptor interactions, and physiological roles of human chorionic gonadotropin (hCG) and its hyperglycosylated variant (hCG-H) during pregnancy.
What was found
The abstract presents mechanistic descriptions without statistical effect sizes or quantitative clinical data. Maternal hCG is primarily produced by the syncytiotrophoblast, peaks at 8–10 weeks of gestation, and signals through the LH/CG receptor to support corpus luteum progesterone secretion, syncytiotrophoblast development, and angiogenesis without altering in vitro trophoblast invasion. Invasive extravillous trophoblasts and choriocarcinoma cells produce hyperglycosylated hCG (hCG-H), which is elevated during the early first trimester and directly stimulates trophoblast invasion and angiogenesis via an LH/CG-R-independent, TGFβ receptor-mediated pathway.
Why it matters
Recognizing that distinct hCG glycoforms signal through different receptor pathways helps explain divergent autocrine, paracrine, and endocrine actions in early pregnancy and supports the investigation of hCG-H as a biomarker for trophoblast invasion and implantation.
Limits
The abstract describes a narrative review without primary empirical data, sample sizes, quantitative estimates, or a systematic search protocol.
Cited by
- supports Human chorionic gonadotropin (hCG) and luteinizing hormone (LH) share the same cellular receptor.